Therapeutic Response

PD-L1 >= 50%, Wild type ALK, Wild type EGFR, and dMMR status confers therapeutic sensitivity to Cemiplimab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Libtayo (cemiplimab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to cemiplimab for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) >= 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: (i) locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or (ii) metastatic.